Conference Coverage
Conference Coverage
AG-221 sparked durable responses in hematologic cancers
Key clinical point: AG-221 could shift the treatment for IDH2 mutation-positive hematologic cancers. Major finding: Fourteen of 25 patients...
Conference Coverage
Inhibitor shows promise for hematologic disorders
Photo courtesy of EHA MILAN—The IDH2 inhibitor AG-221 is well-tolerated and exhibits durable clinical activity in patients with hematologic...
Conference Coverage
Vascular reconstruction may have a role in pancreatic adenocarcinoma resection
Key clinical point: Performing a Whipple on borderline T3 lesions with vascular invasion may allow for an increased amount of surgical resections....
Conference Coverage
Tool predicts lymphoma, death in primary Sjögren’s syndrome patients
Key clinical point: Patients with specific hematologic and immunologic laboratory markers, as well as high degrees of activity in the...
Conference Coverage
Idelalisib efficacy remains rock steady in relapsed CLL
Major finding: Idelalisib and rituximab significantly increased progression-free survival (HR, 0.18; P less than .0001). Data source: A...
Conference Coverage
Refining prognosis in small intestinal neuroendocrine tumors
Key clinical point: The extent of lymph node involvement provides important independent prognostic information in patients with early-stage, T1,...
Conference Coverage
Ruxolitinib improves disease control in PV
©ASCO/Phil McCarten CHICAGO—The JAK1/2 inhibitor ruxolitinib may be a “valuable new treatment option” for patients with polycythemia vera (PV)...
Conference Coverage
Treating HIV+ lymphoma patients
©ASCO/Brian Powers CHICAGO—Hepatitis C reactivation does not worsen survival outcomes for HIV-positive patients diagnosed with lymphoma, new...
Conference Coverage
Studies confirm importance of CALR mutation in PMF
One study showed that PMF patients with mutated CALR had prolonged overall survival (OS) compared to patients with wild-type CALR.
Conference Coverage
Elderly males with DLBCL require increased rituximab dosing
©ASCO/Phil McCarten CHICAGO—Elderly males with non-Hodgkin lymphoma (NHL) may require one-third higher doses of rituximab than the current...
Conference Coverage
Eltrombopag meets primary endpoint in children with ITP
Credit: Logan Tuttle MILAN—Eltrombopag can elicit consistent platelet responses in children with immune thrombocytopenia (ITP), according to...